Next Article in Journal
Addressing Marginality and Exclusion: The Resettlement Experiences of War-Affected Young People in Quebec, Canada
Next Article in Special Issue
Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis
Previous Article in Journal
Significance of Coronary Revascularization for Coronary-Artery Obstructive Lesions Due to Kawasaki Disease
Open AccessCommunication

New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis

1
Department of Dermatology, Hospital Universitario La Paz, 28046 Madrid, Spain
2
Dermatology Group Pedro Jaén, 28002 Madrid, Spain
3
Medical Affairs Department, Cantabria labs, 28043 Madrid, Spain
4
Department of Dermatology, Clínica Universitaria de Navarra, 31008 Pamplona, Spain
*
Authors to whom correspondence should be addressed.
Children 2019, 6(2), 17; https://doi.org/10.3390/children6020017
Received: 20 December 2018 / Revised: 22 January 2019 / Accepted: 22 January 2019 / Published: 29 January 2019
(This article belongs to the Special Issue Atopic Dermatitis and Psoriasis in Children)
Atopic dermatitis (AD) is a chronic cutaneous inflammatory disorder, characterized by skin barrier disruption. Dermacare is a new cosmetic formulation, which enhances moisturization, reinforces and repairs the skin barrier, and prevents cutaneous microbiota imbalance. To demonstrate its safety and efficacy, a prospective, open-label, and multicenter study was carried out on patients diagnosed with mild to moderate AD. Transepidermal water loss (TEWL), clinical severity, Desquamation Index, Patient/Investigator Global Assessments, quality of life index, and tolerance were assessed. Adverse events were recorded. Daily application of the new treatment was well tolerated, and adverse events were absent. After 14 days, TEWL showed a 36.7% significant decrease (p = 0.035). At the end of the 28-day treatment, the Desquamation Index showed a reduction in 70% of patients; Eczema Area and Severity Index were reduced by 70.4% (p = 0.002); and skin irritation showed a significant reduction (p = 0.024). Likewise, Patient and Investigator Global Assessments reported a significant improvement in conditions and an overall global worsening when patients restarted their normal treatment. Parent’s Index of Quality of Life Index significantly increased by 36.4% (p < 0.05) with Dermacare. In conclusion, a regular use of this new formulation can reduce the risk of relapse and extend the steroid-free treatment periods. View Full-Text
Keywords: atopic; dermatitis; emollient; moisturizer; epidermal barrier; filaggrin atopic; dermatitis; emollient; moisturizer; epidermal barrier; filaggrin
Show Figures

Figure 1

MDPI and ACS Style

de Lucas, R.; García-Millán, C.; Pérez-Davó, A.; Moreno, E.; Redondo, P. New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis. Children 2019, 6, 17.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop